Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organ systems and demonstrates marked clinical heterogeneity. The American College of Rheumatology (ACR) classification criteria for SLE include 11 distinct disease manifestations and individuals with any 4 of these 11 features may be classified as having SLE. 1 Some disease manifestations included in the criteria, such as arthritis, photosensitivity and oral ulcers, are relatively mild, whereas others, such as seizures, psychosis, renal involvement and severe hematologic abnormalities, may result in substantial morbidity.
Epidemiologic studies have demonstrated that in the United States, the risk of developing severe SLE manifestations varies by ethnicity, suggesting that genetics may influence disease phenotypes. [2] [3] [4] Recent studies, particularly in Latino populations, have examined genetic admixture in relation to SLE severity, and have shown a trend toward more severe disease with increasing Amerindian ancestry or decreasing European ancestry. 5, 6 Genetic differences within continental populations also provide an opportunity to assess the contribution of genetic ancestry to SLE phenotypes. Within Europe, a genetic gradient spans from northwest to southeast, distinguishing Northern European populations, including British, German, Scandinavian and Eastern European populations, from Southern Europeans, including Italian, Greek and Spanish populations. [7] [8] [9] We have recently demonstrated that Northern and Southern European genetic ancestries are associated with specific SLE phenotypes. In particular, Northern European ancestry is associated with mucocutaneous manifestations of SLE, while Southern European ancestry is a risk factor for autoantibody production. 10 Genetic diversity among European populations, however, is not limited to north-south differences. Recent studies have used principal components analysis (PCA) of genotyping data to detect and describe multiple axes of genetic variation among individuals of European descent. 11, 12 Using PCA, we defined the population genetic substructure for a group of North American SLE cases of European descent. We then examined the relationship between genetic ancestry and specific SLE manifestations to determine whether multiple genetic axes are associated with specific SLE phenotypes.
Results and discussion
Our study population included 1855 North American SLE cases of self-reported European ancestry. Participants were enrolled in four independent case series (Supplementary Table 1 ): the University of California, San Francisco (UCSF) Lupus Genetics Project (n ¼ 1018), the Autoimmune Biomarkers Collaborative Network (ABCoN, n ¼ 338), the University of Pittsburgh Medical Center Lupus Cohort (n ¼ 373) and the Multiple Autoimmune Disease Genetics Consortium (MADGC, n ¼ 126). In each case series, phenotypic information and diagnosis of SLE were confirmed by chart review. Autoantibody status was determined either by chart review or direct serologic testing. An individual was considered autoantibody positive if the presence of an autoantibody was documented at least once either in the medical record or by direct serologic testing. Biological samples and clinical information were collected with written participant consent in accordance with institution-specific protocols and with local Institutional Review Board approval.
All participants had been previously genotyped as part of one of two parent studies. A subset of 1450 participants was genotyped for a genome-wide association study of SLE susceptibility using an Illumina HumanHap550 BeadChip (San Diego, CA, USA) as previously described. 13 The majority of these participants was also included in our previous study of European population substructure and SLE phenotypes. 10 A set of controls (n ¼ 2398) included in the genome-wide association study of SLE susceptibility was also included in these analyses for improved PCA differentiation and interpretation ( Figure 1 ). An additional 405 participants not included in our previous study were genotyped for 12 000 single-nucleotide polymorphisms (SNPs) using an Illumina custom iSELECT Infinium II array.
Clinical and demographic characteristics of the 1631 SLE cases included in the final analysis (see Supplementary Table 1 for exclusions), including the prevalence of SLE manifestations that comprise the 11 ACR classification criteria, are detailed in Supplementary Table 2. As expected for SLE, most participants were female (93.1%), with a mean age at disease onset of 34.9 years (s.d. 13.2). The median disease duration was 7 years (interquartile range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The most common SLE manifestations were antinuclear antibody production (97.0%), arthritis (75.2%) and photosensitivity (72.3%). Less common disease manifestations included discoid rash (8.4%) and fulfillment of the neurologic disorder criterion (9.6%).
Several SLE manifestations tended to occur together and pairwise correlation coefficients for disease manifestations are shown in Figure 2 . Correlation between disease manifestations was assessed using the Spearman's rank-order correlation coefficient. The Spearman's rank-order correlation coefficient was chosen because it makes no assumptions about the nature of the correlation between two variables and can be applied to nonnormally distributed variables. We found that the immunologic disorder and renal disorder criteria were correlated; each was also correlated with the neurologic disorder and hematologic disorder criteria (Pp0.0008). The cutaneous manifestations-photosensitivity, malar rash and discoid rash-were correlated with one another (Pp0.007), whereas photosensitivity was inversely correlated with fulfillment of the renal and immunologic disorder criteria (Pp0.0008).
We applied PCA to a set of 4965 SNPs common to both genotyping platforms for ancestry determination. The first three PCs explained 54% of the variance among the first 10 PCs and had the following eigenvalues and variance: 19.4 (33.3%), 6.7 (11.8%) and 5.1 (9%). The eigenvalues for PC4-PC10 showed a plateau, suggesting that the first three PCs account for most of the population substructure in this analysis.
We used grandparental country of origin of controls to interpret PCs ( Figure 1) . Positive values for the first principal component (PC1) corresponded to Southern European ancestry, while negative values for PC1 corresponded to Northern European ancestry. PC2 defined an east-west gradient, distinguishing Irish from . Points on the graphs represent individual study participants; individuals are color coded according to systemic lupus erythematosus (SLE) status and grandparental country of origin or ethnicity. Population genetic substructure was determined using PCA of 4965 singlenucleotide polymorphisms (SNPs) in EIGENSTRAT (Cambridge, MA, USA). Of these SNPs, 2617 were informative for European population substructure and the remainder were informative for continental ancestry (187 SNPs) or East Asian substructure (2161 SNPs). These SNPs are distributed throughout the autosomal genome and exclude regions of extended linkage disequilibrium (inversion regions and the major histocompatibility complex region). In addition, pairs of SNPs with r 2 40.5 in European population groups, SNPs not in Hardy-Weinberg equilibrium and SNPs missing in 410% of participants were excluded. 11 To improve PC differentiation and interpretation, we also included a set of 2398 controls genotyped for the same set of SNPs. Controls were adults of self-reported European ancestry enrolled in the New York Cancer Project who did not have SLE. 19 Information on grandparental country of origin was collected for controls, and controls with all four grandparents from a single European country or region or who shared a single ethnic identity were used for PC interpretation. Before PCA, we screened the study population for non-European ancestry using a set of 187 ancestry informative markers included in the SNP panel. We used STRUCTURE, a program that applies a model-based, non-hierarchical clustering method for individual ancestry estimation. 20 Participants with 410% non-European ancestry were excluded before PCA to determine European substructure. Participants were also excluded for outlying PC values (46 s.d.s from the mean). AJA, Ashkenazi Jewish ancestry; EEUR, Eastern European.
German and Eastern European ancestry. PC3 distinguished individuals of Ashkenazi Jewish ancestry from other European ancestries. The large variance in PC1 is consistent with previous studies, indicating that the northsouth geographic axis corresponds to the largest component of population substructure within Europe. 8, 9, 11, 14 Next, we examined the relationship between genetic ancestry, represented by the first three PCs, and each of the 11 disease manifestations included in the ACR classification criteria for SLE. We first assessed the bivariate association between each PC, as a continuous variable, and the disease manifestations included in the ACR classification criteria for SLE. For these analyses, we used the Wilcoxon rank-sum test because the PCs, particularly PC1, were not normally distributed. PCs that were associated with a disease manifestation in bivariate analysis (Po0.1) were further evaluated using logistic regression and are included in Table 1. For logistic regression analyses, we first divided each PC into tertiles. Division of the PCs into quantiles was done so that we could compare high and low values within a PC and thus could improve the interpretability of our results. Tertiles were specifically chosen because using three groups maintains quantile size while still preserving some specificity within quantiles. We then used logistic regression to assess the association between PC tertile and disease characteristics, comparing the highest and lowest tertiles within each PC (Table 1) . After adjustment for disease duration, sex and case collection, we found that Southern European ancestry, represented by the highest tertile of PC1, was protective for photosensitivity (odds ratio (OR) highÀlow 0.74, 95% CI 0.56-0.97) and discoid rash (OR highÀlow 0.51, 95% CI 0.32-0.82) and was associated with fulfillment of the renal (OR highÀlow 1.41, 95% CI 1.06-1.87) and immunologic (OR highÀlow ¼ 1.40, 95% CI 1.07-1.83) disorder criteria when compared with Northern European ancestry.
As several autoantibodies are included in the immunologic disorder criterion, we further investigated the relationship between genetic ancestry and production of specific autoantibodies. We found that after adjustment for disease duration, sex and case collection, Southern European ancestry was associated with antidouble-stranded DNA (OR highÀlow ¼ 1.42, 95% CI 1.10-1.83) and anticardiolipin (OR highÀlow ¼ 1.40, 95% CI 1.06-1.84) antibody production ( In a subgroup analysis, we examined whether differences in socioeconomic status among participants could explain our results. Data on educational attainment, a stable measure of socioeconomic status, were available for some participants from the UCSF and ABCoN case collections (n ¼ 799). We repeated the analyses presented in Table 1 , controlling for disease duration, case collection, sex and also for educational attainment. We found that the magnitude and direction of the ORs presented in Table 1 were largely unchanged, although many results did not reach statistical significance because of the sharply reduced sample size and power (data not shown).
Differing environmental exposures, such as sunlight, could also potentially explain our results. Data on place of birth, which may capture some information about environmental exposures, were available for some participants from the UCSF collection (n ¼ 762). We repeated the analyses presented in Table 1 , controlling for disease duration, sex, case collection and place of birth. Again, we found that the magnitude and direction of our results presented in Table 1 were largely unchanged, although because of reduced sample size, many results did not reach statistical significance. Place of birth was not an independent predictor of any disease manifestation except for malar rash (data not shown).
Finally, we observed that when graphed, PC1 and PC3 together defined three distinct clusters of subjects (Figure 1c ): one near controls who reported Ashkenazi Jewish ancestry, a second near controls who reported Southern European ancestry (Greek and Italian) and a Figure 2 Correlation coefficients for systemic lupus erythematosus (SLE) manifestations. We used the Spearman's rank correlation coefficient, which does not require a normal distribution of values for a variable, to assess the correlation between pairs of SLE manifestations included in the American College of Rheumatology classification criteria for SLE and also for specific autoantibodies. Shading reflects the strength and direction of the correlation between SLE phenotypes. *Po0.01; dsDNA, anti-double-stranded DNA antibody; ACL, anticardiolipin antibody; ANA, antinuclear antibody. third large cluster near those who reported Northern European ancestry (German, Irish, Eastern European). We then investigated whether these homogeneous clusters of subjects, defined by two PCs rather than a single PC, demonstrated particular phenotypic associations.
For this analysis, we identified all cases with PC1 and PC3 values within 2 s.d.s of the mean PC1 and PC3 values for controls of self-reported Italian and Greek ancestry (n ¼ 66). We repeated this procedure to identify cases near controls of Ashkenazi Jewish ancestry (n ¼ 68) and cases near controls of Northern European ancestry (n ¼ 1188). We then compared both the Southern European (Italian or Greek) ancestry cluster and the Ashkenazi Jewish ancestry cluster with the Northern European (German, Irish, Eastern European) cluster to examine whether these more homogeneous groups of participants had specific phenotypic associations.
Compared with cases in the Northern European ancestry cluster, cases in the Ashkenazi Jewish ancestry cluster were more likely to meet the immunologic disorder criterion (OR ¼ 1.98, 95% CI 1.09-3.60, P ¼ 0.025) after adjustment for disease duration, sex and case collection. Those in the Ashkenazi Jewish ancestry cluster also had a higher odds of anti-doublestranded DNA antibody production (OR ¼ 1.91, 95% CI 1.13-3.22, P ¼ 0.016) and anticardiolipin antibody production (OR ¼ 1.80, 95% CI 1.05-3.10, P ¼ 0.033) compared with cases in the Northern European cluster after adjustment for disease duration, sex and case collection.
Cases in the Southern European ancestry cluster also had an increased odds of meeting the immunologic disorder criterion (OR ¼ 1.26, 95% CI 0.70-2.27, P ¼ 0.5), anti-double-stranded DNA antibody production (1.47, 95% CI 0.87-2.49, P ¼ 0.2) and anticardiolipin antibody production (OR ¼ 1.41, 95% CI 0.82-2.44, P ¼ 0.2) compared with cases of Northern European ancestry after adjustment for disease duration, sex and cohort. These associations, though, did not reach statistical significance.
Although the Ashkenzi Jewish ancestry cluster had larger, statistically significant ORs for autoantibody production and the Southern European ancestry cluster had smaller, non-statistically significant associations, Wald tests directly comparing the ORs for each phenotype (immunologic disorder criterion, anti-doublestranded DNA antibody production, anticardiolipin antibody production) across the Southern European and Ashkenazi Jewish subgroups were not statistically significant (P40.2). The American College of Rheumatology (ACR) criteria included in this table are disease manifestations that were first shown to be associated with a PC in bivariate analysis (Pp0.1) using the Wilcoxon rank-sum test. For composite criteria that may be fulfilled in several ways, such as the immunologic, hematologic and neurologic disorder criteria, we examined the specific disease manifestations that comprise those criteria if the criteria were associated with the PCs after adjustment for covariates (Pp0.1).
b
For calculation of ORs, we used logistic regression. PCs were divided into tertiles and we compared the highest and lowest tertiles. The reference group for PC1 is the lowest tertile (Northern European ancestry). For PC2, the reference group is the highest tertile (Eastern European ancestry). For PC3 the reference group is the lowest tertile (European, non-Ashkenazi Jewish ancestry).
c For multivariable analyses, we again used logistic regression. PCs were divided into tertiles in the same way as described when calculating crude ORs. Models were adjusted for sex, disease duration and case collection. Analyses were performed using Stata 10.0 (StataCorp., College Station, TX, USA).
Using a non-parametric method for ancestry estimation, an expanded SNP set, and an extended sample, we have identified multiple axes of genetic variation among a population of individuals of European descent. We have also demonstrated that Southern European ancestry is a risk factor for renal disease and autoantibody production and is protective against photosensitivity and discoid rash. Renal disease and autoantibody production are correlated, as are the cutaneous manifestations of SLE, and our findings suggest that a common genetic background may contribute to the development of a particular constellation of SLE manifestations. These findings are consistent with our previous work, which showed that Southern European ancestry is associated with autoantibody production and Northern European ancestry with mucocutaneous manifestations of SLE. 10 The alternative analytic technique and extended sample used here provide further evidence for a more severe SLE phenotype among Southern Europeans.
Epidemiological studies have suggested that SLE may be more prevalent in Southern European countries such as Spain and Italy than in Northern European countries. 15 Intriguingly, the PD1.3A allele of PDCD1, a variant associated with renal manifestations of SLE, is more common among Southern Europeans than Northern Europeans. 16, 17 By contrast, the R620W polymorphism of PTPN22, which has been associated both with the development of SLE and with other autoimmune diseases that demonstrate autoantibody production, is more common among Northern Europeans. 18 These contrasting examples illustrate the complex relationships between genes, populations and development of disease endophenotypes. Nonetheless, geographic variation in alleles associated with SLE and SLE phenotypes supports a plausible role for genetic ancestry in contributing to the development of specific SLE disease manifestations.
In addition to differentiating Northern and Southern European ancestry, PCA also distinguished Eastern and Western European ancestry and separated individuals of Ashkenazi Jewish ancestry from other European ancestries, a finding consistent with previous studies of European population substructure.
11 These additional axes of genetic variation captured less of the variance in the data set and had fewer independent associations with SLE endophenotypes. Nonetheless, we did identify some phenotypic associations with the second and third PC, suggesting that other dimensions of genetic variation beyond north-south differences may have a role in the development of specific SLE manifestations.
Importantly, these additional PCs also provided information for defining more homogeneous clusters of participants among Northern and Southern Europeans. We used information from PC3 to delineate two distinct clusters of participants among those with high PC1 values: those of Ashkenazi Jewish ancestry and those of Southern European ancestry. These two groups shared similar PC1 values and thus demonstrated some genetic similarity. Still, when compared with the same reference group, Northern Europeans, these two groups had varying risks of developing specific SLE manifestations. Although small sample sizes within each subgroup limited our ability to demonstrate that these subgroups definitively differed from one another with respect to phenotypic associations, the varying magnitudes of associations by subgroup suggest that even relatively fine differences in genetic ancestry may confer differential risk for developing specific SLE manifestations.
This study has several limitations. First, participants' clinical data were collected retrospectively, which may result in some misclassification of outcomes due to underreporting or failure to capture disease manifestations that evolve over time. Any misclassification, however, should not differ with respect to genetic ancestry and should bias results toward the null. Second, we examined the association between a number of SLE phenotypes and each of the PCs. This approach led to a large number of hypothesis tests and consequently, an increased likelihood of committing a Type I error. However, a traditional Bonferroni correction is overly conservative, as we have shown that lupus phenotypes are not independent. We have presented unadjusted P-values to allow readers to assess statistical significance. Finally, unmeasured confounders, such as cultural differences or differing environmental exposures among populations, may have contributed to these results. Data on place of residence and socioeconomic status were not available for the entire study population, but our subgroup analyses demonstrated that controlling for birthplace and educational attainment did not substantively alter our results.
In summary, our study has provided further evidence for a more severe SLE phenotype among individuals of Southern European ancestry and suggests that even relatively small differences in population genetics may contribute to disease endophenotypes. Future studies that investigate specific genes that contribute to these phenotypic differences will likely provide invaluable insights into the clinical variability of SLE.
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